Does Rallies show Form 4 insider transactions for PALI?

Yes. Rallies tracks PALI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PALI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PALI. It does not provide personalized investment advice.

PALI (Palisade Bio, Inc. Common Stock) Stock Analysis - Insider Trades

Palisade Bio, Inc. Common Stock (PALI) is a publicly traded Healthcare sector company. As of May 21, 2026, PALI trades at $1.87 with a market cap of $314.54M and a P/E ratio of -6.08. PALI moved +4.42% today. Year to date, PALI is -10.48%; over the trailing twelve months it is +155.12%. Its 52-week range spans $0.53 to $4.32. Analyst consensus is strong buy with an average price target of $10.67. Rallies surfaces PALI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PALI stock inside the company?

Recent PALI insider activity includes Jones Mitchell Lawrence sold 1.99K, Finley John David sold 3.90K, Williams Donald Allen bought 5.00K, Williams Donald Allen bought 5.00K, and Williams Donald Allen bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PALI Key Metrics

Key financial metrics for PALI
Metric	Value
Price	$1.87
Market Cap	$314.54M
P/E Ratio	-6.08
EPS	$-0.30
Dividend Yield	0.00%
52-Week High	$4.32
52-Week Low	$0.53
Volume	54
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-16.78M
Gross Margin	0.00%

Recent PALI Insider Trades

Jones Mitchell Lawrence sold 1.99K (~$3.48K) on Feb 12, 2026.
Finley John David sold 3.90K (~$6.82K) on Feb 12, 2026.
Williams Donald Allen bought 5.00K (~$8.36K) on Jan 16, 2026.
Williams Donald Allen bought 5.00K (~$9.40K) on Jan 9, 2026.
Williams Donald Allen bought 1.00K (~$4.86K) on May 28, 2024.

Latest PALI News

Palisade Bio Reports $132.6M Cash to Fund Phase 2 UC and CD Trials — May 12, 2026
Palisade Bio to Present PALI-2108 Phase 1 Ulcerative Colitis Data Showing Biomarker Gains — Apr 16, 2026
Palisade Bio’s PALI-2108 Sees 47.5% SES-CD Reduction, Advances to Phase 2 — Mar 30, 2026
Palisade Bio’s PALI-2108 Yields 63% UC Score Gain; $138M Runway Extends to 2029 — Mar 1, 2026

PALI Analyst Consensus

6 analysts cover PALI: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.67.

Common questions about PALI

Who is trading PALI stock inside the company?: Recent PALI insider activity includes Jones Mitchell Lawrence sold 1.99K, Finley John David sold 3.90K, Williams Donald Allen bought 5.00K, Williams Donald Allen bought 5.00K, and Williams Donald Allen bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PALI?: Yes. Rallies tracks PALI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PALI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PALI. It does not provide personalized investment advice.